Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2016 August;64(4) > Minerva Cardioangiologica 2016 August;64(4):462-72

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Per citare questo articolo

 

REVIEWS  NEW BIORESORBABLE TECHNOLOGY IN INTERVENTIONAL CARDIOLOGY 

Minerva Cardioangiologica 2016 August;64(4):462-72

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Long-term results of BVS implantation: a focus on safety and efficacy of the bioresorbable technology

Wijnand K. DEN DEKKER, Robert J. VAN GEUNS, Roberto DILETTI

Department of Interventional Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands


PDF


The everolimus eluting bioresorbable vascular scaffold (BVS) represents a novel technology and a novel paradigm for treatment of coronary artery disease, with the potential of improving the long-term clinical outcomes after complete bioresorption. The increasing amount of clinical data is adding in a gradual understanding of the appropriate implantation technique, but long-term results after BVS implantation are sparse. In addition, concern related to a possible increased rate of scaffold thrombosis has recently risen. The present article reviews the current status of knowledge on bioresorbable vascular scaffold from the preclinical phase and the first-in-man experience to the recently reported large randomized trials. Challenging subsets are discussed as well as possible factors impacting on the occurrence of thrombotic events, particularly focusing on clinical outcomes reported in the longest follow-ups currently available.

inizio pagina